Search This Blog

Showing posts with label treatment. Show all posts
Showing posts with label treatment. Show all posts

Saturday, March 17, 2012

Clinic Owners Plead Guilty in Medicare Fraud Scheme

Three Detroit-Area Clinic Owners Plead Guilty for Their Roles in $5.4 Million Medicare Fraud Scheme 

U.S. Department of JusticeMarch 14, 2012
  • Office of Public Affairs(202) 514-2007/TDD (202) 514-1888
WASHINGTON—Three Detroit-area clinic owners pleaded guilty today for their participation in a Medicare fraud scheme, announced the Department of Justice, the FBI, and the Department of Health and Human Services (HHS).
Karina Hernandez, 28; Marieva Briceno, 46; and Henry Briceno, 58, all of Miami, pleaded guilty before U.S. District Judge Arthur J. Tarnow in the Eastern District of Michigan to one count of conspiracy to commit health care fraud. At sentencing, each defendant faces a maximum penalty of 10 years in prison and a $250,000 fine.
According to the plea documents, Hernandez managed the daily operations of three Livonia, Michigan clinics: Blessed Medical Clinic, Alpha & Omega Medical Clinic, and Manuel Medical Clinic. Marieva Briceno contributed capital to fund the opening of one clinic, and assisted her daughter, Hernandez, in the daily management of the clinics. At each clinic, Hernandez and Marieva Briceno hired recruiters who paid cash bribes to Medicare beneficiaries to attend the clinics and provide their Medicare numbers and other information. Hernandez and Marieva Briceno admitted that they used the beneficiary information to bill for medically unnecessary diagnostic tests and treatments. Henry Briceno admitted that he incorporated Manuel Medical Clinic and opened a bank account to conceal the actual ownership of the clinic. According to court documents, Blessed Medical Clinic, Alpha & Omega Medical Clinic, and Manuel Medical Clinic fraudulently billed Medicare for $5.4 million during the course of the scheme.
Today’s guilty pleas were announced by Assistant Attorney General Lanny A. Breuer of the Justice Department’s Criminal Division; U.S. Attorney for the Eastern District of Michigan Barbara L. McQuade; Special Agent in Charge Andrew G. Arena of the FBI’s Detroit Field Office; and Special Agent in Charge Lamont Pugh, III of the HHS Office of Inspector General’s (OIG) Chicago Regional Office.
This case is being prosecuted by Assistant U.S. Attorneys Frances Lee Carlson and Philip A. Ross of the Eastern District of Michigan, with assistance from Assistant Chief Gejaa T. Gobena of the Criminal Division’s Fraud Section. The case was investigated by the FBI and HHS-OIG and was brought as part of the Medicare Fraud Strike Force, supervised by the Criminal Division’s Fraud Section and the U.S. Attorney’s Office for the Eastern District of Michigan.
Since their inception in March 2007, the Medicare Fraud Strike Force operations in nine districts have charged more than 1,190 individuals, who collectively have falsely billed the Medicare program for more than $3.6 billion. In addition, HHS’s Centers for Medicare and Medicaid Services, working in conjunction with the HHS-OIG, is taking steps to increase accountability and decrease the presence of fraudulent providers.

Wednesday, March 14, 2012

Teenager Unlocks Potential Pathways for Breast Cancer Treatments, Wins Intel Science Talent Search

Teenager Unlocks Potential Pathways for Breast Cancer Treatments, Wins Intel Science Talent Search

News Release from IBM - Biomedical Analytics

IBM's Biomedical Analytics Platform Helps Doctors Personalize Treatment

Italy's Istituto Nazionale dei Tumori testing new decision support solutions for cancer treatments
HAIFA, Israel & MILAN - 14 Mar 2012: IBM (NYSE: IBM) today announced it has developed a unique biomedical analytics platform for personalized medicine that could enable doctors to better advise on the best course of medical treatment. This could lead to smarter and more personalized healthcare in a wide-range of areas, including cancer management, hypertension, and AIDS care.
Scientists from IBM Research are collaborating with the Fondazione IRCCS Istituto Nazionale dei Tumori, a major research and treatment cancer center in Italy, on the new decision support solution. This new analytics platform is being tested by the Institute's physicians to personalize treatment based on automated interpretation of pathology guidelines and intelligence from a number of past clinical cases, documented in the hospital information system.
IBM’s Clinical Genomics
IBM’s Clinical Genomics biomedical analytics platform for personalized medicine.
Selecting the most effective treatment can depend on a number of characteristics including  age, weight, family history, current state of the disease and general health.  As a result, more informed and personalized decisions are needed to provide accurate and safe care.
IBM's latest healthcare analytics solution, Clinical Genomics (Cli-G), can integrate and analyze all available clinical knowledge and guidelines, and correlate it with available patient data to create evidence that supports a specific course of treatment for each patient. Developed at IBM Research - Haifa, the new prototype works by investigating the patient's personal makeup and disease profile, and combines this with insight from the analysis of past cases and clinical guidelines. The solution may provide physicians and administrators with a better picture of the patient-care process and reduce costs by helping clinicians choose more effective treatment options.
"Making decisions in today's complex environment requires computerized methods that can analyze the vast amounts of patient information available to ease clinical decision-making," notes Dr. Marco A. Pierotti, Scientific Director at the Istituto Nazionale dei Tumori. "By providing our physicians with vital input on what worked best for patients with similar clinical characteristics, we can help improve treatment effectiveness and the final patient outcome."
Founded in 1925, the Fondazione IRCCS Istituto Nazionale dei Tumori in Milan is recognized as a scientific research and treatment institution in the field of pre-clinical and clinical oncology. The Institute's special status as a research center enables it to transfer research results directly to clinical care. The Institute initiated this collaboration with IBM to enhance patient care through better use of innovative IT solutions. Once physicians make a diagnosis, they will receive personalized insights for their patients, based on medical information, automated interpretation of pathology clinical guidelines, and intelligence from a number of past clinical cases, documented in the hospital information system.
In addition to supporting decision-making about treatment, it can provide administrators at Fondazione IRCCS Istituto Nazionale dei Tumori with an aggregated view of patient care, enabling them to evaluate performances and using this knowledge to streamline processes for maximum safety. For example, hospital administrators can drill down into the data to better understand what the guidelines were for insights, what succeeded, and whether treatment quality has improved.
"Our clinical genomics solution may enable care-givers to personalize treatment and increase its chances of success," explains Haim Nelken, senior manager of integration technologies at IBM Research - Haifa. "The solution is designed to provide physicians with recommendations that go beyond the results of clinical trials. It may allow them to go deeper into the data and more accurately follow the reasoning that led to choices previously made on the basis of subjective memory, intuition, or clinical trial results."
Any patient data securely collected from hospitals and health organizations is 'de-identified' or made anonymous through the removal of personal identifying details. The IBM system does not need to know which individuals the information came from in order to draw conclusions. It works by identifying similar cases based on age, sex, symptoms, diagnosis, or other related factors. 

Thursday, March 1, 2012

News Release from EPA - Armstrong Envtl. Svc.

Armstrong Environmental Services to Pay $35,000 Penalty for Clean Water Act Violations at Lancaster, Pa. Facility 

(PHILADELPHIA – March 1, 2012) The U.S. Environmental Protection Agency today announced a settlement with Armstrong Environmental Services (AES) over alleged Clean Water Act violations at the company’s waste processing and disposal facility in Lancaster, Pa. AES agreed to pay a $35,000 penalty for allegedly exceeding permit limits when discharging industrial wastewater pollutants to the City of Lancaster Wastewater Treatment Plant in Lancaster County, Pa. The settlement also requires the company take actions to minimize the likelihood of future violations.

EPA’s complaint alleged AES exceeded its pretreatment permit discharge limits for pollutants oil and grease, pH and copper for a period of five-years. As part of the settlement, AES did not admit liability for the alleged violations, but has certified that it is now in compliance with applicable Clean Water Act requirements.
 The Clean Water Act requires companies discharging pollutants to publicly owned wastewater treatment works (POTWs) to obtain a permit from the POTW limiting the amount of pollution that may be discharged to the plant. This usually requires some type of pretreatment by the discharging facility.

Pretreatment permit limits for pollutants are established in order to prevent impairment of waterways, either as a result of pollutants passing through the POTW -- or interference with the functioning of the treatment plant.

For more information about pretreatment requirements visit: